PCM
FENC icon

Potomac Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Potomac Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Hold
224,400
– – 1.65% 19
2026
Q1 		$1.38M Buy
224,400
+129,300
+136% +$998K 1.2% 24
2025
Q4 		$732K Buy
+95,100
New +$781K 0.59% 39

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Potomac Capital Management's FENC Position: Q2 2026 in Review

Potomac Capital Management held its Fennec Pharmaceuticals (FENC) position steady in Q2 2026 at 224,400 shares worth $2.41M. The position accounts for 1.65% of the portfolio, ranked #19.

Potomac Capital Management first reported a position in FENC in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Potomac Capital Management held 224,400 shares of Fennec Pharmaceuticals worth $2.41M as of Q2 2026.
  • Potomac Capital Management left its Fennec Pharmaceuticals share count unchanged in Q2 2026.
  • Fennec Pharmaceuticals made up 1.65% of Potomac Capital Management's portfolio in Q2 2026, its #19 holding.
  • Potomac Capital Management first reported a position in Fennec Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Potomac Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.